Search
06/08/2023
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder
Fagiolini A., Cardoner N., Pirildar S., Ittsakul P., Ng B., Duailibi K., El Hindy N.. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder. EXPERT OPINION ON PHARMACOTHERAPY. 2023; 24(15)DOI:10.1080/14656566.2023.2242264. PMID:37501324. IF:2.500(Q3/6D).
01/08/2023
Predictive factors of hesitancy to vaccination against SARS-CoV-2 virus in young adults in Spain: Results from the PSY-COVID study
Mateo-Canedo, C, Sanabria-Mazo, JP, Comendador, L, Rojas, JS, Carmona, M, Crespo-Puig, N, Anyosa, F, Selva, C, Feliu-Soler, A, Cardoner, N, Deus, J, Luciano, JV, Mendez-Ulrich, JL, Sanz, A. Predictive factors of hesitancy to vaccination against SARS-CoV-2 virus in young adults in Spain: Results from the PSY-COVID study. Vaccine: X. 2023; 14DOI:10.1016/j.jvacx.2023.100301. PMID:37091731. IF:(Q/D).
21/07/2023
Opening Treatment Windows for Treatment-Resistant Schizophrenia: Improving Emotion Regulation Strategies Using the Unified Protocol in a Case Study in Spain
Grasa E., Corripio I., Peris-Baquero O., Roldán A., Selma J., Osma J.. Opening Treatment Windows for Treatment-Resistant Schizophrenia: Improving Emotion Regulation Strategies Using the Unified Protocol in a Case Study in Spain. Clinical Case Studies. 2023; DOI:10.1177/15346501231190912. PMID:. IF:0.800(Q4/9D).
15/07/2023
Brain volumetric correlates of electroconvulsive therapy versus transcranial magnetic stimulation for treatment-resistant depression
Cano, M, Lee, E, Polanco, C, Barbour, T, Ellard, KK, Andreou, B, Uribe, S, Henry, ME, Seiner, S, Cardoner, N, Soriano-Mas, C, Camprodon, JA. Brain volumetric correlates of electroconvulsive therapy versus transcranial magnetic stimulation for treatment-resistant depression. JOURNAL OF AFFECTIVE DISORDERS. 2023; 333DOI:10.1016/j.jad.2023.03.093. PMID:37024015. IF:4.900(Q1/2D).
05/07/2023
Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)
Oteo-Álvaro Á., García C.G., Sánchez A.I., Santamaria C.A., de Diego-Adeliño J.. Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS). OSTEOPOROSIS INTERNATIONAL. 2023; 34(10)DOI:10.1007/s00198-023-06838-z. PMID:37405407. IF:4.200(Q1/3D).
05/07/2023
Psychometric validation of the 15-item Questionnaire about the Process of Recovery in Spain (QPR-15-SP)
Goodman-Casanova J.M., Cuesta-Lozano D., Alupoaei C., Bello, EMG, Herrera-Imbroda J., Mayoral-Cleries F., Guzman-Parra J.. Psychometric validation of the 15-item Questionnaire about the Process of Recovery in Spain (QPR-15-SP). Frontiers in Psychology. 2023; 14DOI:10.3389/fpsyg.2023.1178341. PMID:37484089. IF:2.600(Q2/3D).